This ExpertREACT article was originally published on 17 November 2009 following the Meningitis Research Foundation (MRF) meeting in London (12-13 November 2009). Market positions and pipeline data described reflect the state of knowledge at that date.
Meningococcal disease: a persistent public health threat
Neisseria meningitidis accounts for approximately 40% of the estimated 1.2 million annual bacterial meningitis cases worldwide (WHO figures), with serogroups A, C, W and Y together responsible for the majority of disease outside the meningococcal B category. The incidence of meningococcal disease in Western countries ranged from 0.34 cases per 100,000 in the US to 1.1 in Europe at the time of writing, though country variation within Europe was significant - Ireland recorded greater than 4 cases per 100,000. Serogroup Y had become increasingly prevalent in the United States, adding commercial complexity to existing market dynamics dominated by Sanofi Pasteur's Menactra conjugate ACWY vaccine, which sold approximately $730m per year alongside growing contributions from GSK's Menveo and the Wyeth/Pfizer MenHibrix programme.
The success of the UK's meningococcal group C vaccination programme - introduced in 1999 and demonstrating dramatic reductions in serogroup C disease - had established the proof-of-concept benchmark for conjugate meningococcal vaccines in national immunisation programmes. The MRF meeting discussed whether newly licensed ACWY conjugate vaccines could replicate this success in the broader ACWY framework, or whether market penetration would be constrained by the existing Menactra dominance and the uncertain US infant recommendation pathway.
Infant schedule uncertainty as the pivotal issue
VacZine Analytics identified question marks around US infant schedule inclusion for new ACWY conjugate vaccines as the pivotal commercial issue. Without an infant recommendation - currently dominated by Menactra for adolescents - new entrants would need to rely on the adolescent market and expanding international adoption. Manufacturers were being forced to consider alternative penetration strategies including direct-to-consumer campaigns, "at risk" group targeting and international tender opportunities, particularly in the meningitis belt of sub-Saharan Africa where serogroup A posed the highest burden.